Robert C Schneider

Address:

149 Ladue Aire Dr, Saint Louis, MO 63141

Phone:

(314)8785978

VIN:

1N4AL2AP1CC126315

Make:

NISSAN

Model:

ALTIMA

Year:

2012

Address:

11670 Chieftain Dr, Saint Louis, MO 63146

VIN:

1G1ZT58NX7F281767

Make:

CHEVROLET

Model:

MALIBU

Year:

2007

US Patent:

6420338, Jul 16, 2002

Filed:

Jun 13, 1997

Appl. No.:

08/874430

Inventors:

Robert J. Schneider - New York NY
Nicola Klein - New York NY

Assignee:

New York University Medical Center - New York NY

International Classification:

A61K 3857

US Classification:

514 12, 514646, 514258, 514789, 514451, 514619

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

US Patent:

7348178, Mar 25, 2008

Filed:

Oct 17, 1996

Appl. No.:

08/733611

Inventors:

Robert J. Schneider - New York NY, US

Assignee:

New York University Medical Center - New York NY

International Classification:

C12N 15/63
C12N 15/64
C12N 15/861
C12N 15/87
A61K 48/00

US Classification:

435456, 4353201, 435455

Abstract:

The present invention relates to a novel Ad based packaging system that can be used for incorporation of heterologous DNA into infectious but replication defective viral particles. The components of the invention include an “artificial genome”, i. e. , a recombinant vector which contains elements that function as adenovirus replication and packaging signals flanking an intervening DNA sequence. The elements may comprise the minimum genomic Ad sequences required to direct replication of heterologous DNA and packaging into viral particles. The system also includes a means for expressing complementing helper functions to provide in trans viral proteins required for replication and packaging of recombinant viral vectors, but without contaminating the stock of recombinant, trans-packaged viral particles.

US Patent:

7566452, Jul 28, 2009

Filed:

May 4, 1999

Appl. No.:

09/305084

Inventors:

Robert J. Schneider - New York NY, US
Sumayah Jamal - New York NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 39/395
A61K 38/00
G01N 33/53

US Classification:

4241561, 514 2

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

US Patent:

8067000, Nov 29, 2011

Filed:

May 22, 2009

Appl. No.:

12/470589

Inventors:

Robert J. Schneider - New York NY, US
Sumayah Jamal - New York NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 38/00
A61K 39/395
A61P 35/00

US Classification:

4241431, 4241551, 514 133, 514 161, 514 192, 514 193, 514 194, 435 723

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

US Patent:

8597645, Dec 3, 2013

Filed:

Oct 6, 2011

Appl. No.:

13/267360

Inventors:

Robert Schneider - New York NY, US
Sumayah Jamal - New York NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 39/395
A61K 38/00

US Classification:

4241431, 4241561, 514 133, 514 161, 514 192, 514 194

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

US Patent:

20020045191, Apr 18, 2002

Filed:

Sep 17, 2001

Appl. No.:

09/955006

Inventors:

Robert Schneider - New York NY, US
Nicola Klein - Palo Alto CA, US

International Classification:

A61K048/00
A61K038/17
A61K031/519
A61K031/277
A01N037/34
A61K031/275
A01N043/04
A61K031/70
C07H021/04
C12Q001/48
G01N033/53
A61K038/16

US Classification:

435/007100, 514/007000, 514/262100, 514/044000, 514/520000, 435/015000, 536/024500

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

US Patent:

20030032596, Feb 13, 2003

Filed:

Jul 15, 2002

Appl. No.:

10/196344

Inventors:

Robert Schneider - New York NY, US
Nicola Klein - New York NY, US

Assignee:

New York University Medical Center

International Classification:

A61K048/00
A61K038/17
A61K031/519

US Classification:

514/012000, 514/044000, 514/262100

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

US Patent:

20060105327, May 18, 2006

Filed:

Dec 29, 2005

Appl. No.:

11/322863

Inventors:

Robert Schneider - New York NY, US
Nicola Klein - Burlingame CA, US

International Classification:

C12Q 1/70
C12N 1/18
A61K 31/519
A61K 31/275

US Classification:

435005000, 435254200, 514262100, 514521000

Abstract:

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.